ReviewPediatric radiology2026
Pleuropulmonary blastoma and the challenge of distinguishing the cystic form (type I) from other congenital lung malformations.
Review in Pediatric radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pleuropulmonary blastoma is a rare pediatric lung tumor of mesenchymal origin, with prognosis varying by subtype. While types II and III are usually identifiable on imaging due to their solid tumor components, the purely cystic type I represents a particular diagnostic challenge. In imaging, it is often difficult to distinguish from benign congenital lung malformations such as congenital pulmonary airway malformation (CPAM, formerly congenital cystic adenomatoid malformation or CCAM), sequestration, or bronchogenic cyst. Accurate differentiation, however, is clinically relevant, as misclassification may lead to inadequate treatment or an increased risk of disease progression. This article highlights the role of imaging modalities (computed tomography, magnetic resonance imaging, including ultrashort echo time sequences), as well as histopathology and genetics-especially DICER1 mutation-in the diagnosis and therapeutic decision-making of pleuropulmonary blastoma. A modified flowchart based on Feinberg et al. provides practical guidance. For patients with pleuropulmonary blastoma carrying a DICER1 mutation, specific organ-targeted follow-up recommendations are provided to enable early detection of associated tumors.
Indexed as
Identifiers
42012654What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.